|
1
|
Lossos IS: Molecular pathogenesis of
diffuse large B-cell lymphoma. J Clin Oncol. 23:6351–6357. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abramson JS and Shipp MA: Advances in the
biology and therapy of diffuse large B-cell lymphoma: Moving toward
a molecularly targeted approach. Blood. 106:1164–1174. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosenwald A, Wright G, Chan WC, Connors
JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland
EB, Giltnane JM, et al: The use of molecular profiling to predict
survival after chemotherapy for diffuse large-B-cell lymphoma. N
Engl J Med. 346:1937–1947. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coiffier B, Thieblemont C, Van Den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: A study by the Groupe
d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Behm-Ansmant I, Rehwinkel J and Izaurralde
E: MicroRNAs silence gene expression by repressing protein
expression and/or by promoting mRNA decay. Cold Spring Harb Symp
Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Filipowicz W: RNAi: The nuts and bolts of
the RISC machine. Cell. 122:17–20. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
White RE and Giffard RG: MicroRNA-320
induces neurite outgrowth by targeting ARPP-19. Neuroreport.
23:590–595. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ,
Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-320 suppresses the
stem cell-like characteristics of prostate cancer cells by
downregulating the Wnt/beta-catenin signaling pathway.
Carcinogenesis. 34:530–538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bronisz A, Godlewski J, Wallace JA,
Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ,
Martin CK, Li F, et al: Reprogramming of the tumour
microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol.
14:159–167. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhi F, Cao X, Xie X, Wang B, Dong W, Gu W,
Ling Y, Wang R, Yang Y and Liu Y: Identification of circulating
microRNAs as potential biomarkers for detecting acute myeloid
leukemia. PLoS One. 8:e567182013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan Q, Li W, Tang Q, Yao S, Lv Z, Feng N,
Ma X, Bai Z, Zeng Y, Qin D, et al: Cellular microRNAs 498 and 320d
regulate herpes simplex virus 1 induction of Kaposi's
sarcoma-associated herpesvirus lytic replication by targeting RTA.
PLoS One. 8:e558322013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu H, Jiang X, Zhou X, Dong X, Xie K,
Yang C, Jiang H, Sun X and Lu J: Neuropilin-1 regulated by miR-320
contributes to the growth and metastasis of cholangiocarcinoma
cells. Liver Int. 38:125–135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baba Y, Watanabe M, Murata A, Shigaki H,
Miyake K, Ishimoto T, Iwatsuki M, Iwagami S, Yoshida N, Oki E, et
al: LINE-1 hypomethylation, DNA copy number alterations, and CDK6
amplification in esophageal squamous cell carcinoma. Clin Cancer
Res. 20:1114–1124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van Dekken H, van Marion R, Vissers KJ,
Hop WC, Dinjens WN, Tilsanus HW, Wink JC and van Duin M: Molecular
dissection of the chromosome band 7q21 amplicon in gastroesophageal
junction adenocarcinomas identifies cyclin-dependent kinase 6 at
both genomic and protein expression levels. Genes Chromosomes
Cancer. 47:649–656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang G, Zheng L, Yu Z, Liao G, Lu L, Xu R,
Zhao Z and Chen G: Increased cyclin-dependent kinase 6 expression
in bladder cancer. Oncol Lett. 4:43–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsai JW, Li CF, Kao YC, Wang JW, Fang FM,
Wang YH, Wu WR, Wu LC, Hsing CH, Li SH, et al: Recurrent
amplification at 7q21.2 targets CDK6 gene in primary
myxofibrosarcomas and identifies CDK6 overexpression as an
independent adverse prognosticator. Ann Surg Oncol. 19:2716–2725.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Whiteway SL, Harris PS, Venkataraman S,
Alimova I, Birks DK, Donson AM, Foreman NK and Vibhakar R:
Inhibition of cyclin-dependent kinase 6 suppresses cell
proliferation and enhances radiation sensitivity in medulloblastoma
cells. J Neurooncol. 111:113–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu PY, Zhang XD, Zhu J, Guo XY and Wang
JF: Low expression of microRNA-146b-5p and microRNA-320d predicts
poor outcome of large B-cell lymphoma treated with
cyclophosphamide, doxorubicin, vincristine, and prednisone. Hum
Pathol. 45:1664–1673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kluiver J, Poppema S, de Jong D, Blokzijl
T, Harms G, Jacobs S, Kroesen BJ and van den Berg A: BIC and
miR-155 are highly expressed in Hodgkin, primary mediastinal and
diffuse large B cell lymphomas. J Pathol. 207:243–249. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lawrie CH, Soneji S, Marafioti T, Cooper
CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood
J, et al: MicroRNA expression distinguishes between germinal center
B cell-like and activated B cell-like subtypes of diffuse large B
cell lymphoma. Int J Cancer. 121:1156–1161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ, et al: A microRNA polycistron as a potential human
oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roehle A, Hoefig KP, Repsilber D, Thorns
C, Ziepert M, Wesche KO, Thiere M, Loeffler M, Klapper W,
Pfreundschuh M, et al: MicroRNA signatures characterize diffuse
large B-cell lymphomas and follicular lymphomas. Br J Haematol.
142:732–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Högfeldt T, Johnsson P, Grandér D,
Bahnassy AA, Porwit A, Eid S, Österborg A, Zekri AR, Lundahl J,
Khaled MH, et al: Expression of microRNA-1234 related signal
transducer and activator of transcription 3 in patients with
diffuse large B-cell lymphoma of activated B-cell like type from
high and low infectious disease areas. Leuk Lymphoma. 55:1158–1165.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mazan-Mamczarz K, Zhao XF, Dai B,
Steinhardt JJ, Peroutka RJ, Berk KL, Landon AL, Sadowska M, Zhang
Y, Lehrmann E, et al: Down-regulation of eIF4GII by miR-520c-3p
represses diffuse large B cell lymphoma development. PLoS Genet.
10:e10041052014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Geraldo MV, Yamashita AS and Kimura ET:
MicroRNA miR-146b-5p regulates signal transduction of
TGF-β by repressing SMAD4 in thyroid cancer. Oncogene.
31:1910–1922. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van der Linden MH, Willekes M, van Roon E,
Seslija L, Schneider P, Pieters R and Stam RW: MLL fusion-driven
activation of CDK6 potentiates proliferation in MLL-rearranged
infant ALL. Cell Cycle. 13:834–844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lucas JJ, Domenico J and Gelfand EW:
Cyclin-dependent kinase 6 inhibits proliferation of human mammary
epithelial cells. Mol Cancer Res. 2:105–114. 2004.PubMed/NCBI
|
|
32
|
Wang Y, Li Y, Sun J, Wang Q, Sun C, Yan Y,
Yu L, Cheng D, An T, Shi C, et al: Tumor-suppressive effects of
miR-29c on gliomas. Neuroreport. 24:637–645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Z, Huang L, Yu Z, Chen X, Yang D,
Zhan P, Dai M, Huang S, Han Z and Cao K: Let-7a functions as a
tumor suppressor in Ewing's sarcoma cell lines partly by targeting
cyclin-dependent kinase 6. DNA Cell Biol. 33:136–147. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Classon M and Harlow E: The retinoblastoma
tumour suppressor in development and cancer. Nat Rev Cancer.
2:910–917. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bustos MA, Ono S, Marzese DM, Oyama T,
Iida Y, Cheung G, Nelson N, Hsu SC, Yu Q and Hoon DSB: MiR-200a
regulates CDK4/6 inhibitor effect by targeting CDK6 in metastatic
melanoma. J Invest Dermatol. 137:1955–1964. 2017. View Article : Google Scholar : PubMed/NCBI
|
